Vascular dysfunction in S1P2 sphingosine 1-phosphate receptor knockout mice

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 292, Issue 1, 2007, Pages

  Lorenz, John N ^a   Arend, Lois J ^a   Robitz, Rachel ^a   Paul, Richard J ^a   MacLennan, A John ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Blood flow; Endothelium; Lysosphingolipids; Myocardial contractility; Vascular smooth muscle

Indexed keywords

PHENYLEPHRINE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; CARDIOTONIC AGENT; DOBUTAMINE; POTASSIUM CHLORIDE; VASOCONSTRICTOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FLOW MEASUREMENT; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HISTOPATHOLOGY; IN VITRO STUDY; KNOCKOUT MOUSE; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VASCULAR RING; VASOCONSTRICTION; ANIMAL; BLOOD FLOW; DOSE RESPONSE; DRUG EFFECT; GENETICS; KIDNEY CIRCULATION; MOUSE MUTANT; MUSCLE CONTRACTION; MUSCLE TONE; PATHOPHYSIOLOGY; PHYSIOLOGY; SPLANCHNIC BLOOD FLOW; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE;

ANIMALS; BLOOD PRESSURE; CARDIOTONIC AGENTS; DOBUTAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; MICE; MICE, KNOCKOUT; MUSCLE CONTRACTION; MUSCLE TONUS; MUSCLE, SMOOTH, VASCULAR; POTASSIUM CHLORIDE; RECEPTORS, LYSOSPHINGOLIPID; REGIONAL BLOOD FLOW; RENAL CIRCULATION; SPLANCHNIC CIRCULATION; VASCULAR DISEASES; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS;

EID: 33846135087     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00085.2006     Document Type: Article

References (36)

1. Alewijnse AE, Peters SL, Michel MC. Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites. Br J Pharmacol 143: 666-684, 2004.
2. Bischoff A, Czyborra P, Fetscher C, Meyer Zu Heringdorf D, Jakobs KH, and Michel MC. Sphingosine-1-phosphate and sphingosylphosphorylcholine constrict renal and mesenteric microvessels in vitro. Br J Pharmacol 130: 1871-1877, 2000.
3. Bischoff A, Czyborra P, Meyer Zu Heringdorf D, Jakobs KH. and Michel MC. Sphingosine-1-phosphate reduces rat renal and mesenteric blood flow in vivo in a pertussis toxin-sensitive manner. Br J Pharmacol 130: 1878-1883, 2000.
4. Bischoff A, Meyer Zu Heringdorf D, Jakobs KH, and Michel MC. Lysosphingolipid receptor-mediated diuresis and natriuresis in anaesthetized rats. Br J Pharmacol 132: 1925-1933, 2001.
5. Bolz SS, Vogel L, Sollinger D, Derwand R, Boer C, Pitson SM, Spiegel S, Pohl U. Sphingosine kinase modulates microvascular tone and myogenic responses through activation of RhoA/Rho kinase. Circulation 108: 342-347, 2003.
6. Chun J, Goetzl EJ, Hla T, Igarashi Y, Lynch KR, Moolenaar W, Pyne S, Tigyi G. International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev 54: 265-269, 2002.
7. Coussin F, Scott RH, Wise A, Nixon GF. Comparison of sphingosine 1-phosphate-induced intracellular signaling pathways in vascular smooth muscles: differential role in vasoconstriction. Circ Res 91: 151-157, 2002.
8. Dantas AP, Igarashi J, Michel T. Sphingosine 1-phosphate and control of vascular tone. Am J Physiol Heart Circ Physiol 284: H2045-H2052, 2003.
9. Forrest M, Sun SY, Hajdu R, Bergstrom J, Card D, Doherty G, Hale J, Keohane C, Meyers C, Milligan J, Mills S, Nomura N, Rosen H, Rosenbach M, Shei GJ, Singer II, Tian M, West S, White V, Xie J, Proia RL, Mandala S. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther 309: 758-768, 2004.
10. Goetzl EJ, An S. Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. FASEB J 12: 1589-1598, 1998.
11. Guo J, MacDonell KL, Giles WR. Effects of sphingosine 1-phosphate on pacemaker activity in rabbit sino-atrial node cells. Pflügers Arch 438: 642-648, 1999.
12. Hedemann J, Fetscher C, Michel MC. Comparison of noradrenaline and lysosphingolipid-induced vasoconstriction in mouse and rat small mesenteric arteries. Auton Autacoid Pharmacol 24: 77-85, 2004.
13. Hsiao SH, Constable PD, Smith GW, Haschek WM. Effects of exogenous sphinganine, sphingosine, and sphingosine-1-phosphate on relaxation and contraction of porcine thoracic aortic and pulmonary arterial rings. Toxicol Sci 86: 194-199, 2005.
14. Ikeda H, Nagashima K, Yanase M, Tomiya T, Arai M, Inoue Y, Tejima K, Nishikawa T, Watanabe N, Omata M, Fujiwara K. Sphingosine 1-phosphate enhances portal pressure in isolated perfused liver via S1P2 with Rho activation. Biochem Biophys Res Commun 320: 754-759, 2004.
15. Ishii I, Ye X, Friedman B, Kawamura S, Contos JJ, Kingsbury MA, Yang AH, Zhang G, Brown JH, Chun J. Marked perinatal lethality and cellular signaling deficits in mice null for the two sphingosine 1-phosphate (S1P) receptors, S1P(2)/LP(B2)/EDG-5 and S1P(3)/LP(B3)/EDG-3. J Biol Chem 277: 25152-25159, 2002.
16. Jin ZQ, Goetzl EJ, Karliner JS. Sphingosine kinase activation mediates ischemic preconditioning in murine heart. Circulation 110: 1980-1989, 2004.
17. Jin ZQ, Zhou HZ, Zhu P, Honbo N, Mochly-Rosen D, Messing RO, Goetzl EJ, Karliner JS, Gray MO. Cardioprotection mediated by sphingosine-1- phosphate and ganglioside GM-1 in wild-type and PKCε knockout mouse hearts. Am J Physiol Heart Circ Physiol 282: H1970-H1977, 2002.
18. Karliner JS. Mechanisms of cardioprotection by lysophospholipids. J Cell Biochem 92: 1095-1103, 2004.
19. Lalli J, Harrer JM, Luo W, Kranias EG, Paul RJ. Targeted ablation of the phospholamban gene is associated with a marked decrease in sensitivity in aortic smooth muscle. Circ Res 80: 506-513, 1997.
20. Lorenz JN. A practical guide to evaluating cardiovascular, renal, and pulmonary function in mice. Am J Physiol Regul Integr Comp Physiol 282: R1565-R1582, 2002.
21. Lorenz JN, Robbins J. Measurement of intraventricular pressure and cardiac performance in the intact closed-chest anesthetized mouse. Am J Physiol Heart Circ Physiol 272: H1137-H1146, 1997.
22. MacLennan AJ, Carney PR, Zhu WJ, Chaves AH, Garcia J, Grimes JR, Anderson KJ, Roper SN, Lee N. An essential role for the H218/AGR16/Edg-5/ LP(B2) sphingosine 1-phosphate receptor in neuronal excitability. Eur J Neurosci 14: 203-209, 2001.
23. Moolenaar WH. Bioactive lysophospholipids and their G protein-coupled receptors. Exp Cell Res 253: 230-238, 1999.
24. Nofer JR, van der Giet M, Tolle M, Wolinska I, von Wnuck Lipinski K, Baba HA, Tietge UJ, Godecke A, Ishii I, Kleuser B, Schafers M, Fobker M, Zidek W, Assmann G, Chun J, and Levkau B. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 113: 569-581, 2004.
25. Ohmori T, Yatomi Y, Osada M, Kazama F, Takafuta T, Ikeda H, Ozaki Y. Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. Cardiovasc Res 58: 170-177, 2003.
26. Ohmori T, Yatomi Y, Osada M, Ozaki Y. Platelet-derived sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. J Thromb Haemost 2: 203-205, 2004.
27. Osada M, Yatomi Y, Ohmori T, Ikeda H, Ozaki Y. Enhancement of sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist. Biochem Biophys Res Commun 299: 483-487, 2002.
28. Pyne S, Rakhit S, Conway AM, McKie A, Darroch P, Tate R, Pyne N. Extracellular actions of sphingosine I-phosphate through endothelial differentiation gene products in mammalian cells: role in regulating proliferation and apoptosis. Biochem Soc Trans 27: 404-409, 1999.
29. Salomone S, Yoshimura S, Reuter U, Foley M, Thomas SS, Moskowitz MA, Waeber C. S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate. Eur J Pharmacol 469: 125-134, 2003.
30. Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, Peterson MS, Webb B, Lefebvre S, Chun J, Gray N, Rosen H. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 279: 13839-13848, 2004.
31. Sekiguchi K, Yokoyama T, Kurabayashi M, Okajima F, Nagai R. Sphingosylphosphorylcholine induces a hypertrophic growth response through the mitogen-activated protein kinase signaling cascade in rat neonatal cardiac myocytes. Circ Res 85: 1000-1008, 1999.
32. Sugiyama A, Aye NN, Yatomi Y, Ozaki Y, Hashimoto K. Effects of sphingosine 1-phosphate, a naturally occurring biologically active lysophospholipid, on the rat cardiovascular system. Jpn J Pharmacol 82: 338-342, 2000.
33. Sugiyama A, Yatomi Y, Ozaki Y, Hashimoto K. Sphingosine 1-phosphate induces sinus tachycardia and coronary vasoconstriction in the canine heart. Cardiovasc Res 46: 119-125, 2000.
34. Taha TA, Hannun YA, Obeid LM. Sphingosine kinase: biochemical and cellular regulation and role in disease. J Biochem Mol Biol 39: 113-131, 2006.
35. Tosaka M, Okajima F, Hashiba Y, Saito N, Nagano T, Watanabe T, Kimura T, Sasaki T. Sphingosine 1-phosphate contracts canine basilar arteries in vitro and in vivo: possible role in pathogenesis of cerebral vasospasm. Stroke 32: 2913-2919, 2001.
36. Watterson KR, Ratz PH, Spiegel S. The role of sphingosine-1- phosphate in smooth muscle contraction. Cell Signal 17: 289-298, 2005.